Global Hepatitis C Drugs

Hepatitis C Drugs Comprehensive Study by Type (NS5A Inhibitor (Protease Inhibitors), Fixed-dose Combination, Others), Application (Hospitals, Clinics), Disease (Acute Hepatitis C, Chronic Hepatitis C), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Players and Region - Global Market Outlook to 2030

Hepatitis C Drugs Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 2.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Hepatitis C Drugs Market Overview:
Hepatitis C is basically a disease causes inflammation and infection of the liver. Such condition develops when some one is infected with the virus of hepatitis C that is (HCV). Hepatitis C can be either chronic or acute. Till now there are no vaccine develop for the hepatitis C. Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage. Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market. Increasing number of regulatory approvals will boost the global hepatitis C market in the forthcoming years. While high cost of drugs limits access to the drugs for low and middle-class patients which, in turn, hampers market growth. As per latest study released by AMA Research, the Global Hepatitis C Drugs market is expected to see growth rate of 2.7%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Research and development activities in the pharmaceutical industry and Hepatitis C Drugs vendors are introducing products with a high storage capacity

Market Growth Drivers:
Increasing incidence of hepatitis C and Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market

Challenges:
High cost of hepatitis C drugs, especially direct-acting antivirals

Restraints:
Several side effects is leading to permanent damage

Opportunities:
Increasing number of regulatory approvals and increasing number of voluntary licensing agreements

Competitive Landscape:
The market of Hepatitis C Drugs is growing due to the rising incidences of Hepatitis C. The top players present in the market are striving hard for research in market of Hepatitis C drugs availability. Along with it high cost of the drug is further creating competitive structure among some players for cost cut down.
Some of the key players profiled in the report are Gilead sciences (United States), Abbvi (United States), Johnson & Johnson (United States), Merck (United States), Glaxosmithkline (United Kingdom), Novartis (Switzerland), Bristol-Myers Squibb (United States) and Roche (Switzerland). Considering Market by Disease, the sub-segment i.e. Acute Hepatitis C will boost the Hepatitis C Drugs market. Considering Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the Hepatitis C Drugs market.

Latest Market Insights:
In February 2021, Gilead Sciences announced the completion of its acquisition of Merck & Co's hepatology business, which included Hepatitis C drugs.

In July 2021, AbbVie and Royalty Pharma formed a strategic partnership to commercialize AbbVie's investigational Hepatitis C treatment in specific territories.

What Can be Explored with the Hepatitis C Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Hepatitis C Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Hepatitis C Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Hepatitis C Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Hepatitis C Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Industry Investors, Manufacturers, End User Industries, Hospitals, Laboratories, Traders, Distributors, and Suppliers, Government and Research Organizations and Associations and Industry Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • NS5A Inhibitor (Protease Inhibitors)
  • Fixed-dose Combination
  • Others
By Application
  • Hospitals
  • Clinics
By Disease
  • Acute Hepatitis C
  • Chronic Hepatitis C

By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing incidence of hepatitis C
      • 3.2.2. Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market
    • 3.3. Market Challenges
      • 3.3.1. High cost of hepatitis C drugs, especially direct-acting antivirals
    • 3.4. Market Trends
      • 3.4.1. Research and development activities in the pharmaceutical industry
      • 3.4.2. Hepatitis C Drugs vendors are introducing products with a high storage capacity
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hepatitis C Drugs, by Type, Application, Disease, Distribution Channel and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hepatitis C Drugs (Value)
      • 5.2.1. Global Hepatitis C Drugs by: Type (Value)
        • 5.2.1.1. NS5A Inhibitor (Protease Inhibitors)
        • 5.2.1.2. Fixed-dose Combination
        • 5.2.1.3. Others
      • 5.2.2. Global Hepatitis C Drugs by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
      • 5.2.3. Global Hepatitis C Drugs by: Disease (Value)
        • 5.2.3.1. Acute Hepatitis C
        • 5.2.3.2. Chronic Hepatitis C
      • 5.2.4. Global Hepatitis C Drugs by: Distribution Channel (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Retail Pharmacies
        • 5.2.4.3. Online Pharmacies
      • 5.2.5. Global Hepatitis C Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Hepatitis C Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gilead sciences (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbvi (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Glaxosmithkline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Hepatitis C Drugs Sale, by Type, Application, Disease, Distribution Channel and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hepatitis C Drugs (Value)
      • 7.2.1. Global Hepatitis C Drugs by: Type (Value)
        • 7.2.1.1. NS5A Inhibitor (Protease Inhibitors)
        • 7.2.1.2. Fixed-dose Combination
        • 7.2.1.3. Others
      • 7.2.2. Global Hepatitis C Drugs by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
      • 7.2.3. Global Hepatitis C Drugs by: Disease (Value)
        • 7.2.3.1. Acute Hepatitis C
        • 7.2.3.2. Chronic Hepatitis C
      • 7.2.4. Global Hepatitis C Drugs by: Distribution Channel (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Retail Pharmacies
        • 7.2.4.3. Online Pharmacies
      • 7.2.5. Global Hepatitis C Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hepatitis C Drugs: by Type(USD Million)
  • Table 2. Hepatitis C Drugs NS5A Inhibitor (Protease Inhibitors) , by Region USD Million (2018-2023)
  • Table 3. Hepatitis C Drugs Fixed-dose Combination , by Region USD Million (2018-2023)
  • Table 4. Hepatitis C Drugs Others , by Region USD Million (2018-2023)
  • Table 5. Hepatitis C Drugs: by Application(USD Million)
  • Table 6. Hepatitis C Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 7. Hepatitis C Drugs Clinics , by Region USD Million (2018-2023)
  • Table 8. Hepatitis C Drugs: by Disease(USD Million)
  • Table 9. Hepatitis C Drugs Acute Hepatitis C , by Region USD Million (2018-2023)
  • Table 10. Hepatitis C Drugs Chronic Hepatitis C , by Region USD Million (2018-2023)
  • Table 11. Hepatitis C Drugs: by Distribution Channel(USD Million)
  • Table 12. Hepatitis C Drugs Hospital Pharmacies , by Region USD Million (2018-2023)
  • Table 13. Hepatitis C Drugs Retail Pharmacies , by Region USD Million (2018-2023)
  • Table 14. Hepatitis C Drugs Online Pharmacies , by Region USD Million (2018-2023)
  • Table 15. South America Hepatitis C Drugs, by Country USD Million (2018-2023)
  • Table 16. South America Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 17. South America Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 18. South America Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 19. South America Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 20. Brazil Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 21. Brazil Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 22. Brazil Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 23. Brazil Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 24. Argentina Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 25. Argentina Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 26. Argentina Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 27. Argentina Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 28. Rest of South America Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 29. Rest of South America Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 30. Rest of South America Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 31. Rest of South America Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 32. Asia Pacific Hepatitis C Drugs, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 34. Asia Pacific Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 35. Asia Pacific Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 36. Asia Pacific Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 37. China Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 38. China Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 39. China Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 40. China Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 41. Japan Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 42. Japan Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 43. Japan Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 44. Japan Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 45. India Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 46. India Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 47. India Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 48. India Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 49. South Korea Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 50. South Korea Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 51. South Korea Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 52. South Korea Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 53. Taiwan Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 54. Taiwan Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 55. Taiwan Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 56. Taiwan Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 57. Australia Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 58. Australia Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 59. Australia Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 60. Australia Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 65. Europe Hepatitis C Drugs, by Country USD Million (2018-2023)
  • Table 66. Europe Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 67. Europe Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 68. Europe Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 69. Europe Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 70. Germany Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 71. Germany Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 72. Germany Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 73. Germany Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 74. France Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 75. France Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 76. France Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 77. France Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 78. Italy Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 79. Italy Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 80. Italy Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 81. Italy Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 82. United Kingdom Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 83. United Kingdom Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 84. United Kingdom Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 85. United Kingdom Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 86. Netherlands Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 87. Netherlands Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 88. Netherlands Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 89. Netherlands Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 90. Rest of Europe Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 91. Rest of Europe Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 92. Rest of Europe Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 93. Rest of Europe Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 94. MEA Hepatitis C Drugs, by Country USD Million (2018-2023)
  • Table 95. MEA Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 96. MEA Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 97. MEA Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 98. MEA Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 99. Middle East Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 100. Middle East Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 101. Middle East Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 102. Middle East Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 103. Africa Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 104. Africa Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 105. Africa Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 106. Africa Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 107. North America Hepatitis C Drugs, by Country USD Million (2018-2023)
  • Table 108. North America Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 109. North America Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 110. North America Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 111. North America Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 112. United States Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 113. United States Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 114. United States Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 115. United States Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 116. Canada Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 117. Canada Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 118. Canada Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 119. Canada Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 120. Mexico Hepatitis C Drugs, by Type USD Million (2018-2023)
  • Table 121. Mexico Hepatitis C Drugs, by Application USD Million (2018-2023)
  • Table 122. Mexico Hepatitis C Drugs, by Disease USD Million (2018-2023)
  • Table 123. Mexico Hepatitis C Drugs, by Distribution Channel USD Million (2018-2023)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Hepatitis C Drugs: by Type(USD Million)
  • Table 133. Hepatitis C Drugs NS5A Inhibitor (Protease Inhibitors) , by Region USD Million (2025-2030)
  • Table 134. Hepatitis C Drugs Fixed-dose Combination , by Region USD Million (2025-2030)
  • Table 135. Hepatitis C Drugs Others , by Region USD Million (2025-2030)
  • Table 136. Hepatitis C Drugs: by Application(USD Million)
  • Table 137. Hepatitis C Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 138. Hepatitis C Drugs Clinics , by Region USD Million (2025-2030)
  • Table 139. Hepatitis C Drugs: by Disease(USD Million)
  • Table 140. Hepatitis C Drugs Acute Hepatitis C , by Region USD Million (2025-2030)
  • Table 141. Hepatitis C Drugs Chronic Hepatitis C , by Region USD Million (2025-2030)
  • Table 142. Hepatitis C Drugs: by Distribution Channel(USD Million)
  • Table 143. Hepatitis C Drugs Hospital Pharmacies , by Region USD Million (2025-2030)
  • Table 144. Hepatitis C Drugs Retail Pharmacies , by Region USD Million (2025-2030)
  • Table 145. Hepatitis C Drugs Online Pharmacies , by Region USD Million (2025-2030)
  • Table 146. South America Hepatitis C Drugs, by Country USD Million (2025-2030)
  • Table 147. South America Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 148. South America Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 149. South America Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 150. South America Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 151. Brazil Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 152. Brazil Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 153. Brazil Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 154. Brazil Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 155. Argentina Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 156. Argentina Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 157. Argentina Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 158. Argentina Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 159. Rest of South America Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 160. Rest of South America Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 161. Rest of South America Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 162. Rest of South America Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 163. Asia Pacific Hepatitis C Drugs, by Country USD Million (2025-2030)
  • Table 164. Asia Pacific Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 165. Asia Pacific Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 166. Asia Pacific Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 167. Asia Pacific Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 168. China Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 169. China Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 170. China Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 171. China Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 172. Japan Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 173. Japan Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 174. Japan Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 175. Japan Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 176. India Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 177. India Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 178. India Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 179. India Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 180. South Korea Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 181. South Korea Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 182. South Korea Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 183. South Korea Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 184. Taiwan Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 185. Taiwan Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 186. Taiwan Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 187. Taiwan Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 188. Australia Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 189. Australia Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 190. Australia Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 191. Australia Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 192. Rest of Asia-Pacific Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 193. Rest of Asia-Pacific Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 196. Europe Hepatitis C Drugs, by Country USD Million (2025-2030)
  • Table 197. Europe Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 198. Europe Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 199. Europe Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 200. Europe Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 201. Germany Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 202. Germany Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 203. Germany Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 204. Germany Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 205. France Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 206. France Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 207. France Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 208. France Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 209. Italy Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 210. Italy Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 211. Italy Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 212. Italy Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 213. United Kingdom Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 214. United Kingdom Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 215. United Kingdom Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 216. United Kingdom Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 217. Netherlands Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 218. Netherlands Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 219. Netherlands Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 220. Netherlands Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 221. Rest of Europe Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 222. Rest of Europe Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 223. Rest of Europe Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 224. Rest of Europe Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 225. MEA Hepatitis C Drugs, by Country USD Million (2025-2030)
  • Table 226. MEA Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 227. MEA Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 228. MEA Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 229. MEA Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 230. Middle East Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 231. Middle East Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 232. Middle East Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 233. Middle East Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 234. Africa Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 235. Africa Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 236. Africa Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 237. Africa Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 238. North America Hepatitis C Drugs, by Country USD Million (2025-2030)
  • Table 239. North America Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 240. North America Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 241. North America Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 242. North America Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 243. United States Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 244. United States Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 245. United States Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 246. United States Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 247. Canada Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 248. Canada Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 249. Canada Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 250. Canada Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 251. Mexico Hepatitis C Drugs, by Type USD Million (2025-2030)
  • Table 252. Mexico Hepatitis C Drugs, by Application USD Million (2025-2030)
  • Table 253. Mexico Hepatitis C Drugs, by Disease USD Million (2025-2030)
  • Table 254. Mexico Hepatitis C Drugs, by Distribution Channel USD Million (2025-2030)
  • Table 255. Research Programs/Design for This Report
  • Table 256. Key Data Information from Secondary Sources
  • Table 257. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hepatitis C Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Hepatitis C Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Hepatitis C Drugs: by Disease USD Million (2018-2023)
  • Figure 7. Global Hepatitis C Drugs: by Distribution Channel USD Million (2018-2023)
  • Figure 8. South America Hepatitis C Drugs Share (%), by Country
  • Figure 9. Asia Pacific Hepatitis C Drugs Share (%), by Country
  • Figure 10. Europe Hepatitis C Drugs Share (%), by Country
  • Figure 11. MEA Hepatitis C Drugs Share (%), by Country
  • Figure 12. North America Hepatitis C Drugs Share (%), by Country
  • Figure 13. Global Hepatitis C Drugs share by Players 2023 (%)
  • Figure 14. Global Hepatitis C Drugs share by Players (Top 3) 2023(%)
  • Figure 15. Global Hepatitis C Drugs share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Gilead sciences (United States) Revenue, Net Income and Gross profit
  • Figure 18. Gilead sciences (United States) Revenue: by Geography 2023
  • Figure 19. Abbvi (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbvi (United States) Revenue: by Geography 2023
  • Figure 21. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 22. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 23. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 24. Merck (United States) Revenue: by Geography 2023
  • Figure 25. Glaxosmithkline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. Glaxosmithkline (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 29. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 30. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 31. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 32. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 33. Global Hepatitis C Drugs: by Type USD Million (2025-2030)
  • Figure 34. Global Hepatitis C Drugs: by Application USD Million (2025-2030)
  • Figure 35. Global Hepatitis C Drugs: by Disease USD Million (2025-2030)
  • Figure 36. Global Hepatitis C Drugs: by Distribution Channel USD Million (2025-2030)
  • Figure 37. South America Hepatitis C Drugs Share (%), by Country
  • Figure 38. Asia Pacific Hepatitis C Drugs Share (%), by Country
  • Figure 39. Europe Hepatitis C Drugs Share (%), by Country
  • Figure 40. MEA Hepatitis C Drugs Share (%), by Country
  • Figure 41. North America Hepatitis C Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Gilead sciences (United States)
  • Abbvi (United States)
  • Johnson & Johnson (United States)
  • Merck (United States)
  • Glaxosmithkline (United Kingdom)
  • Novartis (Switzerland)
  • Bristol-Myers Squibb (United States)
  • Roche (Switzerland)
Select User Access Type

Key Highlights of Report


Mar 2024 225 Pages 61 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hepatitis C Drugs Quantitative research analysis
Global Hepatitis C Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Hepatitis C Drugs market are Gilead sciences (United States), Abbvi (United States), Johnson & Johnson (United States), Merck (United States), Glaxosmithkline (United Kingdom), Novartis (Switzerland), Bristol-Myers Squibb (United States) and Roche (Switzerland), to name a few.
"Research and development activities in the pharmaceutical industry " is seen as one of major influencing trends for Hepatitis C Drugs Market during projected period 2023-2030.
NS5A Inhibitor (Protease Inhibitors) segment in Global market to hold robust market share owing to "Increasing incidence of hepatitis C ".

Know More About Global Hepatitis C Drugs Report?

Have a Query? Click Here

Other Related Reports

Human Vaccines Comprehensive Study by Type (Live-Attenuated Vaccines, Inactivated Vaccines, Subunit, Recombinant, Polysaccharide, and Conjugate Vaccines, Toxoid Vaccines), Distribution Channel (Hospi...
$ 3450
Thin Film Drug Comprehensive Study by Type (Transdermal Film, Oral Thin Film), Application (Hospitals, Clinics, Others), Indication Type (Schizophrenia, Migraine, Opioid Dependence, Nausea & Vomiting...
$ 3750
Infusion Pharmacy Management Comprehensive Study by Type (Antibiotics, Antimicrobial, Pain Management, Enteral Nutrition, Others), Application (Hospital & Clinic, Ambulatory Surgical Centers, Home Ca...
$ 3350
Active Pharma Ingredient Comprehensive Study by Type (Innovative Active Pharmaceutical Ingredients, Generic Active Pharmaceutical Ingredients), Application (Oncology, Cardiovascular Disease, Diabetes...
$ 3750
Kinase Inhibitors Comprehensive Study by Type (Tyrosin Kinase Inhibitors (TKI), Receptor Tyrosine Kinase Inhibitors, Non-Receptor Tyrosine Kinase Inhibitors, Mulikinase Inhibitors, Threonine Kinase I...
$ 3750
Eye Care Products Comprehensive Study by Type (Artificial Tear Drops, Ointments or Emollients, Eye Washes, Hyperosomotics, Eyelid Scrubs, Decongestants, Antihistamines), Form (Cream, Solution, Other...
$ 3450